Lv42
740 积分 2023-09-17 加入
1006-P: Real-World Effectiveness of Semaglutide in Early Users from a U.S. Commercially Insured (CI) and Medicare Advantage (MA) Population
18天前
已关闭
Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function
18天前
已完结
Exploring two dose regimens of ITCA 650 to switch from stable liraglutide therapy in patients with type 2 diabetes
18天前
已完结
Switching GLP-1 agonists: Effects on glucose and blood pressure
19天前
已完结
新诊断2型糖尿病肥胖患者早期联合不同剂型GLP-1RA对胰岛β细胞功能的影响
19天前
已完结
Switching to iGlarLixi vs continuation of glucagon-like peptide-1 receptor agonist in inadequately controlled type 2 diabetes: the randomised LixiLan-G trial
19天前
已关闭
Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
19天前
已关闭
Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series
19天前
已完结
Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance
24天前
已完结
皖公网安备34019202002308
